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HIGHLY PURIFIED MURINE INTERLEUKIN 5 (IL-5)
STIMULATES EOSINOPHIL FUNCTION AND PROLONGS
IN VITRO SURVIVAL
IL-5 as an Eosinophil Chemotactic Factor
By YUJI YAMAGUCHI,* YOSHIHIKO HAYASHI,I YASUO SUGAMA,' YASUSADA
MIURA,* TADASHI KASAHARA,1 SATOSHI KITAMURA,' MASAMICHI TORISUJ
SEIJI MITA,$ AKIRA TOMINAGA,4 KIYOSHI TAKATSU,4 AND TOSHIO SUDA*
From the *Division ofHematology, Department of Medicine,Jichi Medical School, Tochigi-Ken;
the IDivision of Clinical Immunology, First Department of Surgery, School of Medicine,
University ofKyushu, Fukuoka; the 'Division ofPulmonary Medicine, Department ofMedicine,
and the IDeparlment of Medical Biology and Parasitology, Jichi Medical School, Tochigi-Ken;
and the 'Department ofBiology, Institutefor Medical Immunology, Kumamoto University
Medical School, Kumamoto, Japan
A B cell-active factor termed T cell-replacing factor (TRF) derived from the
B151 T cell hybridoma has been shown to promote IgM secretion by the BCLI
B cell line and to induce hapten-specific IgG secretion in vitro by in vivo anti-
gen-primed B cells (1-3). Recently, the gene structure of TRF has been deter-
mined, and TRF has been revealed to enhance the production of IgA by mouse
B cells (4) and induce IL-2 receptors on B cells (5). It also acts as eosinophil
differentiation factor (6). Because of these multiple activities, this TRF was pro-
posed to be called interleukin 5 (IL-5). More recently, we demonstrated that
highly purified IL-5 supported the terminal differentiation and proliferation of
murine eosinophilic precursors (7). In this study, to elucidate whether IL-5
increases the functional properties of mature eosinophils, we examined its
effects on the survival, the superoxide anion production, and the chemotactic
activities of murine mature eosinophils.
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Hemopoietic Factors.
￿
We used TRF as rIL-5, which was synthesized as described pre-
viously (8). Briefly, pSP6K-mTRF23 was cleaved with Sal I to linearize the plasmid DNA,
and mRNAs were synthesized using SP6 RNA polymerase. The synthesized RNAs were
injected into Xenopus oocytes, and their conditioned medium was collected after incu-
bation for 36 h at 20°C, and purified using an anti-TRF antibody-coupled affinity column
(9) . 1 U of IL-5 was defined as the reciprocal of the dilution yielding a response that is
50% of the maximal response to the stimulation activity of BCLI cells. Human recom-
binant granulocyte colony-stimulating factor (rG-CSF) was generously provided by Chu-
gai Pharmaceutical Co. (Tokyo, Japan) and had a specific activity of 2.5-10.0 X 10'/mg
protein (10). Activities and lineage specificities of human G-CSF were not significantly
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different from those of murine G-CSF in murine hemopoietic cells (7). Murine granu-
locyte/macrophage CSF (GM-CSF) was provided by Sumitomo Pharmaceutical Co.
(Osaka,Japan) (11). It had a specific activity of 3.7 X 10" U/mg protein. We used super-
natant of COS cells transfected with cDNA of IL-3 which was provided by Dr. T. Yokota
(DNAX, Palo Alto, CA) (12). It had a specific activity of 105 U/mg protein.
Mice and Cell Preparation.
￿
Inbred female BALB/c mice, 8-15 wk old, were purchased
from Shizuoka Experimental Animal Center (Shizuoka, Japan). We collected eosinophil-
rich peritoneal exudate cells by modifying the method described previously (7). Briefly,
mice were intraperitoneally injected with 200 mg/kg cyclophosphamide (Shionogi Co.,
Osaka, Japan), and 2 d later were infected by 1,000 Toxocara canis larvae with oral admin-
istration. 12 d after the infection, 1 ml of a 0.2 mg/ml (protein concentration) Anisakis
extract was injected intraperitoneally, and the peritoneal exudate cells (PEC) were col-
lected 48 h later. These PEC contained 52% eosinophils, 42% macrophages, 4% lympho-
cytes, 1% neutrophils, and 1% mast cells. Thereafter, the PEC were isolated by density
gradient centrifugation in polyvinylpyrrolidone-coated silica gel (Percoll ; Pharmacia Fine
Chemicals, Uppsala, Sweden), and enriched eosinophils constituted the layer below 50%
Percoll. This preparation always contained >90% eosinophils with an average purity of
90-97%, and was used for the following experiments.
Cell Culture.
￿
Liquid cultures of mature eosinophils were performed using 24-well tis-
sue culture plates (Coster, Cambridge, MA), and each well contained 2 ml alpha medium
supplemented with 20% FCS, 106 eosinophils, a CSF such as purified human rG-CSF,
murine rGM-CSF, and murine rIL-3 or murine rIL-5. At various times, viable cells were
counted by eosin exclusion, and differential counts were made on cytospin preparations
stained with May-Grunwald-Giemsa. PEC were cultured using a methylcellulose culture
method (13) . 1 ml of culture medium contained 105 PEC, alpha medium, 1 .2% deionized
BSA (Sigma Chemical Co. St. Louis, MO), 0.1 mM mercaptoethanol (Sigma Chemical
Co.), and 8 U of IL-5. The cultures were incubated at 37°C in a humidified atmosphere
of 5% COI in air. Colonies were counted on day 7 of culture.
Eosinophil Functions. Superoxide anion production by eosinophils was assayed by
superoxide dismutase inhibitable cytochrome c reduction spectrophotometrically, and
the continuous assay was performed in a Hitachi 557 spectrophotometer (a dual wave-
length spectrophotometer; Hitachi Ltd., Tokyo, Japan). The reduction of cytochrome c
was measured at 550 nm with a reference wavelength at 540 nm and the release of super-
oxide anion was calculated from cytochrome c reduced for 3 min after the addition of
IL-5.
The in vitro chemotactic activity of IL-5 on eosinophils was measured by a modifica-
tion by Boyden's chamber technique as described by Ward et al (14) . Briefly, the cham-
ber consisted of two compartments separated by a Millipore membrane (pore size of 5
,m in diameter). Eosinophils were placed in the upper compartment and the culture
medium containing various concentrations of IL-5 was placed in the lower compartment.
To know whether IL-5 is truly an eosinophil chemotactic factor, we carried out the
checkerboard assay (15), which is the method to determine if eosinophils could respond
to positive and negative gradients of IL-5 . Various concentrations of 11-5 were respec-
tively added into the two compartments separated by a Millipore membrane . The cham-
bers were incubated for 4 h at 37°C in 5% COI, and chemotactic activity was assessed in
terms of the number of cells migrating from the upper surface to the opposite side of
the filter. The membranes were stained according to Litt's procedure (16).
Results and Discussion
IL-5 was able to support eosinophil survival up to 10 d, whereas in its absence
the number of eosinophils began to decrease and few viable cells could be
detected on day 8 (Fig. 1). The length of survival depended on the dose of IL-
5. No mitotic figures of eosinophils were observed in the cytospin preparation
stained with May-Grunwald-Giemsa. To determine whether the longer eosino-
phil survival by the addition of IL-5 was due to the recruitment from newlyproliferating eosinophils by IL-5, we tested whether PEC contain hemopoietic
precursor cells by methylcellulose culture. No colony formation was observed by
4 X 105 PECs in the presence of 8 U/ml IL-5.
Fig. 2 shows the effects of various CSF on the survival of mature eosinophils.
G-CSF and IL-3 did not maintain the viability of eosinophils. GM-CSF sup-
ported eosinophil survival only for the first 4 d of culture. On the other hand,
in the presence of IL-5 the eosinophils remained viable for 16 days.
The proliferation and differentiation of eosinophilic precursors are stimulated
by GM-CSF, IL-3, and IL-5; however, the effects on mature eosinophils differed
among them. From our previous (7) and present results, it could be concluded
that IL-5 is a lymphokine that acts preferentially on terminal differentiation of
eosinophils and maintains their survival. By contrast, IL-3 supports the differ-
entiation of early hemopoietic precursor cells to form the eosinophils, until they
are morphologically recognizable .
We examined the effects of IL-5 on superoxide anion production by eosino-
phils. IL-5 dose dependently induced superoxide anion production, with a pla-
teau being reached at a concentration of 16 U/ml IL-5 (Fig. 3) . The grade of
this superoxide anion production of eosinophils was comparable for that upon
stimulation with 0.16 nM PMA (Sigma Chemical Co.) . Lopez et al. (17) recently
reported that cloned gibbon IL-3 stimulated the function of purified human
mature eosinophils (17). It remains to be clarified whether this effect was com-
parable to IL-5 or GM-CSF.
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FIGURE 1. In vitro survival of
mature eosinophils in the presence
of IL-5. At various times, the viable
cell number was counted usingeosin
exclusion, and differential counts
were carried out by examination of
cytocentrifuge preparations stained
with May-Grunwald-Giemsa. Each
value is the mean of data of an
experiment performed in duplicate
cultures. Control means the absence
Days in culture
￿
of CSF.
FIGURE 2. In vitro survival of mature
eosinophils when cultured in the absence
of CSF (open circle) or in the presence of 20
ng/ml G-CSF (closed circle), 100 U/ml II-3
(closed square), 100 U/ml GM-CSF (open
square), or 8 U/ml IL-5 (open triangle). The
number of viable cells was counted at var-
ious times using eosin exclusion. Each
Days in culture
￿
value is the mean of duplicate cultures.1740
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Effect of IL-5 on the super-
oxide anion production of eosinophils.
Mature eosinophils were prepared as
described in the text. Superoxide anion
production was assayed spectrophoto-
metrically by the reduction of cyto
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Table I shows that IL-5 had a highly chemokinetic effect on eosinophils in a
dose-dependent manner when it was added only in the lower compartment of
the chambers at concentration from 2 to 32 U/ml . As shown in Fig. 4, the
results of the checkerboard assay indicate that IL-5 enhanced migration in a
positive gradient and that it is an eosinophil chemotactic factor.
Several investigators have studied the specific stimuli for eosinophil chemo-
taxis and migration. Among them, eosinophil stimulation promotor (ESP) is a
lymphokine that stimulates eosinophil migration (18). The eosinophil chemotac-
tic factor of anaphylaxis (ECF-A) is a mast cell-derived factor that enhances the
eosinophil's capacity to kill worms (19). However, no factors supporting both
proliferation of eosinophil'c precursors and stimulating eosinophil functions
have been reported.
We found that rIL-5 maintained eosinophil viability, induced superoxide
anion production by eosinophils, and had eosinophil chemotactic activity. IL-5
may be produced locally at inflammatory sites and then may mobilize eosinophils
to inflammatory foci from circulating blood, and stimulate phagocytosis by
enhancing superoxide release. These eosinophils could be recruited by IL-5,
which specifically stimulates the terminal differentiation and amplification of
eosinophils.
TABLE I
In Vitro Chemokinetic Activity of IL-5 for Eosinophils
* This activity is expressed as the total count ofmigrated cells on the 10 high power
fields of micropore filter. Data are represented as the mean ± SD of three
experiments.
Materials Chemokinetic effect*
Buffer (1X Hanks' BSS) 26 ± 2.3
IL-5 (U/ml):
2 31 ± 3.5
4 48 ± 7.9
8 55 ± 5.0
16 100 ± 13
32 148 ± 62once tretion of IL-5 above filler
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Summary
The recent molecular cloning of the complementary DNA encoding T cell-
replacing factor (TRF) has demonstrated that a single molecule is responsible
for B cell growth factor II (BCGF-II) activity and eosinophil differentiation
activity. It has been proposed that this molecule be called interleukin 5 (IL-5).
We previously reported that purified rIL-5 supports the terminal differentiation
and proliferation of eosinophilic precursors. In this study, we examined the
effects of IL-5 on functional activities of mature eosinophils. IL-5 maintained
the viability of mature eosinophils obtained from peritoneal exudate cells of
mice infected with parasites. It also induced superoxide anion production in a
dose-dependent manner. The Boyden's chamber Millipore assay revealed that
IL-5 had a marked chemokinetic effect on eosinophils in a dose-dependent man-
ner. Moreover, IL-5 was found to be an eosinophil chemotactic factor by the
checkerboard assay. In conclusion, IL-5 is suggested to play an important role
in increasing the functional activities of eosinophils as well as their production
in allergic and parasitic diseases.
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FIGURE 4. Checkerboard assay of IL-5 on eosinophils. Values
represent the mean of duplicate filters.
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